pubmed.ncbi.nlm.nih.gov

The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor - PubMed

️Wed Jan 01 2003

Review

The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor

Rainer H Böger. Cardiovasc Res. 2003.

Abstract

There is abundant evidence that the endothelium plays a crucial role in the maintenance of vascular tone and structure. One of the major endothelium-derived vasoactive mediators is nitric oxide (NO). Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthase. ADMA inhibits vascular NO production at concentrations found in pathophysiological conditions (i.e., 3-15 micromol/l); ADMA also causes local vasoconstriction when it is infused intraarterially. The biochemical and physiological pathways related to ADMA are now well understood: dimethylarginines are the result of the degradation of methylated proteins; the methyl group is derived from S-adenosylmethionine. Both ADMA and its regioisomer, SDMA, are eliminated from the body by renal excretion, whereas only ADMA, but not SDMA, is metabolized via hydrolytic degradation to citrulline and dimethylamine by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). DDAH activity and/or expression may therefore contribute to the pathogenesis of endothelial dysfunction in various diseases. ADMA is increased in the plasma of humans with hypercholesterolemia, atherosclerosis, hypertension, chronic renal failure, and chronic heart failure. Increased ADMA levels are associated with reduced NO synthesis as assessed by impaired endothelium-dependent vasodilation. In several prospective and cross-sectional studies, ADMA evolved as a marker of cardiovascular risk. With our increasing knowledge of the role of ADMA in the pathogenesis of cardiovascular disease, ADMA is becoming a goal for pharmacotherapeutic intervention. Among other treatments, the administration of L-arginine has been shown to improve endothelium-dependent vascular function in subjects with high ADMA levels.

PubMed Disclaimer

Cited by

Association between Nfr2, HO-1, NF-kB Expression, Plasma ADMA, and Oxidative Stress in Metabolic Syndrome.
Bekyarova GY, Vankova DG, Madjova VH, Bekyarov NA, Salim AS, Ivanova DG, Stoeva SM, Gerova DI, Kiselova-Kaneva YD. Bekyarova GY, et al. Int J Mol Sci. 2023 Dec 2;24(23):17067. doi: 10.3390/ijms242317067. Int J Mol Sci. 2023. PMID: 38069389 Free PMC article.
Asymmetric dimethylarginine in homocystinuria due to cystathionine beta-synthase deficiency: relevance of renal function.
Wilcken DE, Wang J, Sim AS, Green K, Wilcken B. Wilcken DE, et al. J Inherit Metab Dis. 2006 Feb;29(1):30-7. doi: 10.1007/s10545-006-0208-0. J Inherit Metab Dis. 2006. PMID: 16601865
Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder?
Kelleher RJ, Soiza RL. Kelleher RJ, et al. Am J Cardiovasc Dis. 2013 Nov 1;3(4):197-226. Am J Cardiovasc Dis. 2013. PMID: 24224133 Free PMC article. Review.
Clinical evaluation of extracellular ADMA concentrations in human blood and adipose tissue.
May M, Batkai S, Zörner AA, Tsikas D, Jordan J, Engeli S. May M, et al. Int J Mol Sci. 2014 Jan 17;15(1):1189-200. doi: 10.3390/ijms15011189. Int J Mol Sci. 2014. PMID: 24445256 Free PMC article.
High levels of asymmetric dimethylarginine are strongly associated with low HDL in patients with acute myocardial infarction.
Lorin J, Guilland JC, Korandji C, Touzery C, Bichat F, Chagnon A, Cottin Y, Rochette L, Vergely C, Zeller M. Lorin J, et al. PLoS One. 2013 Jun 6;8(6):e64796. doi: 10.1371/journal.pone.0064796. Print 2013. PLoS One. 2013. PMID: 23755144 Free PMC article.

The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor - PubMed